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AbstrAct
Introduction Ankle fracture surgery is a common procedure, 
but the influence of anaesthesia choice on postoperative 
pain and quality of recovery is poorly understood. Some 
authors suggest a benefit of peripheral nerve block 
(PNB) in elective procedures, but the different pain profile 
following acute fracture surgery and the rebound pain on 
cessation of the PNB both remain unexplored. We present 
an ongoing randomised study aiming to compare primary 
PNB anaesthesia with spinal anaesthesia for ankle fracture 
surgery regarding postoperative pain profiles and quality of 
recovery.
Methods and analysis AnAnkle Trial is a randomised, dual-
centre, open-label, blinded analysis trial of 150 adult patients 
undergoing primary internal fixation of an ankle fracture. 
Main exclusion criteria are habitual opioid use, impaired pain 
sensation, other painful injuries or cognitive impairment. The 
intervention is ultrasound-guided popliteal sciatic (20 mL) 
and saphenal nerve (8 mL) PNB with ropivacaine 7.5 mg/
mL, and controls receive spinal anaesthesia (2 mL) with 
hyperbaric bupivacaine 5 mg/mL. Postoperatively all receive 
paracetamol, ibuprofen and patient-controlled intravenous 
morphine on demand. Morphine consumption and pain 
scores are registered in the first 27 hours and reported as 
an integrated pain score as the primary endpoint. Pain score 
intervals are 3 hours and we will use the area under curve 
to get a longitudinal measure of pain. Secondary outcomes 
include rebound pain on cessation of anaesthesia, opioid 
side effects (Opioid-Related Symptom Distress Scale), quality 
of recovery (Danish Quality of Recovery-15 score) and pain 
scores and medication days 1–7 (diary).
Ethics and dissemination The study has been approved 
by the Regional Ethics Committees in the Capital Region of 
Denmark, the Danish Data Protection Agency and the Danish 
Health and Medical Authority. We will publish the results in 
international peer-reviewed medical journals.
Trial registration number AnAnkle Trial is registered 
in the European Clinical Trials Database (EudraCT 2015-
001108-76).
IntroductIon
Peripheral nerve blocks (PNB) are getting 
increasingly popular for both primary anaes-
thesia and postoperative pain control in 
orthopaedic limb surgery, but its suitability 
for acute fracture surgery is not well estab-
lished.
Ankle fracture is a common acute condi-
tion, which often requires surgery.1 2 There is 
no evidence-based consensus regarding the 
best choice of anaesthesia modality for this 
high-volume procedure, and the influence of 
this choice on the postoperative pain profile is 
poorly understood. Spinal anaesthesia (SA) is 
most common, but PNBs are becoming widely 
implemented, as they provide long-lasting pain 
control and are regarded very safe.3–7 There 
is some evidence that PNBs used in elective 
surgical procedures on knee, ankle and foot 
are effective in reducing pain, opioid consump-
tion and related side effects such as nausea 
and vomiting, as well as potentially reducing 
length of hospital stay and increasing patient 
satisfaction.4 8–16 However, PNBs can represent 
a logistical challenge in the acute setting and, 
moreover, the pain profile following fractures 
and fracture surgery is naturally different from 
that of conditions requiring elective surgery.
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Protocol
Strengths and limitations of this study
 ► This is the first trial to thoroughly investigate the 
postoperative pain profile and directly compare 
the most commonly used regional anaesthesia 
techniques for ankle fracture surgery.
 ► The trial is randomised and designed with attention 
to allocation concealment and stratification to 
prevent selection bias.
 ► The primary endpoint is a composite measure of 
pain and morphine consumption, which holds more 
statistical power than when analysing either of the 
two components alone.
 ► Blinding of participants and investigators is not 
feasible; thus, the trial is open-labelled with blinded 
data analysis.
group.bmj.com on December 1, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
2 Sort R, et al. BMJ Open 2017;7:e016001. doi:10.1136/bmjopen-2017-016001
Open Access 
Very few studies have investigated the efficacy and 
possible benefits of PNBs in this context and results 
are incongruous. One randomised study of postopera-
tive pain scores in ankle fracture surgery showed initial 
benefit with PNB added to general anaesthesia but also 
revealed a sizeable ‘rebound pain’ on cessation of the 
PNBs, which could challenge the overall benefit on the 
postoperative pain profile.17 Another randomised study 
of bimalleolar fracture surgery patients showed a longer 
postoperative effect of PNB anaesthesia compared with SA 
measured as time to first analgesic request, but pain levels 
were not measured.18 At our centre, a large retrospec-
tive study of postoperative opioid consumption in ankle 
fracture surgery has suggested that the largest benefit 
of the regional anaesthesia modalities is obtained with 
PNBs.19 However, in a prospective exploratory pilot study 
investigating primary PNB anaesthesia for ankle fracture 
surgery, we also found a clear indication of rebound pain 
in relation to cessation of the PNB effect, especially in 
younger individuals (abstract published).20
We hypothesise the following:
1. PNB anaesthesia for ankle fracture surgery reduces 
overall postoperative pain, opioid use and opioid-
related side effects compared with SA.
2. Rebound pain following cessation of PNB 
anaesthesia is more pronounced than rebound 
pain following cessation of SA after ankle fracture 
surgery.
3. Patient-reported quality of recovery after ankle 
fracture surgery is better following PNB anaesthesia 
than following SA.
We therefore aim to assess the postoperative pain 
profile and quality of recovery after acute ankle fracture 




AnAnkle Trial is a prospective, randomised, parallel 
group, dual-centre, open-label, blinded analysis trial 
designed to assess the postoperative pain profile and 
quality of recovery following ankle fracture surgery 
under PNB anaesthesia compared with SA. The study 
is conducted in two university hospitals in the Capital 
Region of Denmark. Trial participants are randomly 
assigned to either SA or PNB anaesthesia as described 
below. Primary data are patient-reported pain scores and 
on demand morphine consumption reported as an inte-
grated pain score (IPS).
Participant eligibility and consent
Treating physicians consecutively identify eligible subjects 
according to the listed criteria. Eligible subjects receive 
written and oral information and are included after 
anaesthesiologist investigators have obtained informed 
written consent.
Inclusion criteria
1. Scheduled for internal fixation of an ankle fracture.
2. Age >18 years.
3. Ability to read and understand Danish and give 
informed written consent.
Exclusion criteria
1. Allergy towards non-steroidal anti-inflammatory 
drugs, paracetamol, morphine or local anaesthetics.
2. Bodyweight <52 kg to avoid toxic doses of local 
anaesthetics.
3. Contraindications for SA.
4. Current gastrointestinal bleeding.
5. Proximal fibular fracture or multitrauma/other 
simultaneous fractures.
6. Cognitive or psychiatric dysfunction or alcohol/
narcotic substance abuse causing expected inability 
to comply with study protocol.
7. No available anaesthesiologist with PNB capability 
at scheduled time of operation.
8. Neuropathy/neurological dysfunction in the lower 
extremities.
9. Habitual daily use of opioids.
10. Pregnancy or breast feeding.
11. Infection at anaesthesia injection site.
12. Nephropathy requiring dialysis.
13. Acute porphyria.
recruitment period
All legislative and ethical approvals were obtained and the 
trial registered in the European Clinical Trials Database 
(EudraCT 2015-001108-76) by June 2015.21 22 Inclusion 
was initiated in July 2015 and will continue until 150 
patients have been included and their primary outcome 
data secured in an expected inclusion period of 22–24 
months.
sample size estimation
The target sample size for AnAnkle Trial is 150 partici-
pants. This estimation for the primary outcome (IPS) 
is based on the O’Brien Castello formula by calculating 
Wilcoxon-Mann-Whitney odds (WMW odds) for sample 
sizing in non-parametric statistics.23 24 Prior studies have 
shown a positive correlation between the two parame-
ters on which the IPS is based, that is, higher pain scores 
are associated with a higher opioid consumption and 
vice versa.23 Using data from our observational study, 
we designed the trial to be able to detect a simultaneous 
30% difference in both morphine consumption and pain 
scores as we consider this a clinically meaningful differ-
ence. We did not plan any interim analyses.
This results in WMW odds=1.75. With a power of 80% 
(β=20%) and two-sided significance level α=5%, the 
resulting sample size is 141 patients. Adding 6% to adjust 
for protocol violations results in a final sample size of 150 
(2×75) patients to include.
We also conducted sample size estimations for the 
following key secondary outcomes, which were all found 
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to be covered by the set sample size: numeric rating 
scale pain score area under the curve (NRS-AUC) for a 
rebound period of 6 hours with 50% intergroup differ-
ence; rebound IPS of 6 hours with 30% difference; 
NRS-AUC of 0–27 hours with 30% difference; morphine 
consumption of 0–27 hours with 30% difference; and 
quality of recovery score with 10% difference. All 
outcomes are listed below.
randomisation and allocation concealment
Randomisation is externally managed, computer-gener-
ated and irreversible. The allocation and participant trial 
identification number is retrieved via a secured website, 
with an allocation ratio of 1:1 between PNB and SA. The 
sequence is stratified by trial centre and patient age group 
(≤60 or >60 years of age) and performed as block rando-
misation with variable block sizes that are unknown to 
the investigators to maintain allocation concealment. We 
thereby follow the International Conference on Harmon-
isation (ICH) guideline for Good Clinical Practice 
(GCP) and minimise possible bias from uneven inclusion 
between centres and age groups with potentially different 
pain profiles.
Blinding
The trial is open-labelled. Thus, investigators and partic-
ipants are not blinded, but data will be blinded by an 
independent consultant before analysis.
The difference in anaesthesia application between 
the groups (spinal in the lower back and PNB at lower 
thigh level) combined with the characteristic differences 
in onset and duration of anaesthesia makes blinding of 
both participants and physicians administering the anaes-
thesia effectively impossible. PNBs must be administered 
well before the surgery to ensure sufficient onset time, 
whereas SA is best administered shortly before surgery 
to ensure adequate duration. A clear difference in dura-
tion of the anaesthesia effect between groups is expected, 
which renders blinding of data collectors ineffective. 
Data for the main outcomes are registered directly by the 
participants (pain scores) or electronically (morphine 
patient-controlled analgesia (PCA) pump). Patients do 
not need to consult with staff to take morphine. The 
collected data will be anonymised and blinded by an 
external consultant, not otherwise involved in the trial, 
before statistical analysis is performed.
Interventions
Intervention group: PNB as ultrasound-guided popliteal 
sciatic nerve block and midfemoral saphenal nerve block 
with ropivacaine hydrochloride 7.5 mg/mL. We use a 
fixed dose of 20 mL (150 mg) for the sciatic nerve and 
8 mL (60 mg) for the saphenal nerve to minimise the risk 
of toxic reactions. Unsuccessful block of a single nerve 
(tibial, peroneal or saphenal), defined as no effect on 
sensory function after 40–45 min or insufficient effect 
after 60 min, is supplemented with an additional dose of 
5 mL or 10 mL provided the patient is weighing 62–71 kg 
or >72 kg, respectively, thus staying within recommended 
total dosage of 4 mg/kg of ropivacaine.
Control group: standard SA using hyperbaric bupiva-
caine 5 mg/mL, 2.0 mL.
Both groups: small doses of midazolam, propofol or 
similar can be offered on demand during administration 
of spinal or PNB anaesthesia to help remedy any anxiety. 
Both groups will be offered light to moderate sedation 
during the operation with intravenous propofol. If neces-
sary, intravenous boluses of short-action opioid such as 
fentanyl or sufentanil can be administered.
Standard postoperative pain medication regimen: 
tablet paracetamol 1000 mg ×4, tablet ibuprofen 400 mg 
×3 and intravenous morphine via a PCA pump system 
delivering 2.5 mg of morphine on demand with a 6 min 
lockout period. The morphine is changed to tablets 
5–10 mg on demand after 27 hours.
outcomes
Primary outcome measure
 ► IPS for the period 0–27 hours postanaesthesia. 
IPS is based on NRS-AUC and total morphine 
consumption. NRS pain score is registered every 
3 hours.
The 27-hour primary study period was defined from 
experiences gained in the observational pilot study 
to ensure that we capture the full period of potential 
rebound pain in both groups. The PNBs lasted a mean 
of 16.5 hours, and rebound pain stabilised and subsided 
within a maximum of about 6 hours. We chose time of 
anaesthesia as starting point rather than time of surgery 
because logistical challenges can result in fairly large vari-
ations in time from PNB administration to surgery.
Secondary outcome measures
 ► Rebound pain: IPS for a 6-hour period from patient-
reported time of cessation of the sensory block (PNB 
or spinal) in the ankle.
 ► NRS-AUC pain 0–27 hours postanaesthesia.
 ► Morphine use 0–27 hours (PCA pump).
 ► Opioid adverse effects 0–27 hours: clinically 
meaningful events (CME) assessed with the 
composite Opioid-Related Symptom Distress Scale 
(OR-SDS).25 26
 ► Quality of recovery (Danish Quality of Recovery-15 
score)27 0–27 hours.
 ► ‘Risk patients’, that is, number of patients with 
IPS +100 to +200 (=high pain and high morphine 
consumption).
 ► Peak NRS pain score 0–27 hours.
 ► ‘High pain patients’, that is, number of patients 
reaching peak NRS ≥7.
Tertiary outcome measures
 ► NRS pain scores postoperative (PO) days 1–7.
 ► Need for on-demand opioids PO days 2–7.
 ► Opioid adverse effects PO day 2: CMEs assessed by 
the composite OR-SDS score.
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 ► Overall patient satisfaction with anaesthesia form 
including postoperative pain control, NRS score.
 ► Adverse events/adverse reactions (AEs).
 ► Postoperative nerve-related symptoms on PO day 7.
The OR-SDS questionnaire has been validated in 
English.25 26 28 We conducted a Danish translation for 
AnAnkle Trial using two independent medical doctors, 
bilingual in English and Danish. Disagreements were 
discussed with the principal investigator, and minor 
adjustments were made in a second round after testing 
the translated version on eight patients.
data management, audit and safety
Only data necessary for evaluation of the stated outcomes, 
safety parameters and possible confounders are collected, 
and only after inclusion and randomisation on retrieving 
informed written consent.
For every included patient, a case report form is devised 
for registration of all data except morphine use, which 
is electronically registered by the PCA pump and saved 
as patient-specific files. Data sources include patient-re-
ported pain scores, questionnaires and diary, electronic 
patient files and the PCA morphine data files. The NRS 
pain scores are registered directly by the patients on 
paper. They also note the time of return of sensation to 
the ankle.
All data are marked and handled according to GCP 
standards and legislative permission by the Danish Data 
Protection Agency.
Safety
Any AEs within five half-lives of the intervention drugs are 
registered and classified using the Common Terminology 
Criteria for Adverse Events.29 All severe AEs (SAEs) are 
reported to the responsible trial sponsor and followed 
until stabilised or resolved. If an SAE meets the criteria 
for reporting, it is forwarded immediately to the Danish 
Medicines Agency and the Ethics Committee.
The trial will be stopped in its entirety in the unlikely 
event that incidence and severity of AEs compromise the 
safety of trial participants as evaluated by the trial group 
or by the Danish Medicines Agency.
AnAnkle Trial is monitored by the independent GCP 
unit at Copenhagen University Hospital through regular 
auditing visits to both trial centres, thus ensuring adher-
ence to GCP guidelines as well as proper handling and 
reporting of AEs.
Protocol violations and participant withdrawal
Protocol violations
 ► Failed spinal or PNB (defined as change of 
anaesthesia modality necessary).
 ► Glucocorticoids or controlled-release opioids 
administered on the day of surgery.
Participants meeting any one of these criteria will not 
be excluded and data are collected as planned. Data will 
be included in an intention-to-treat (ITT) analysis but 
omitted in per-protocol analyses.
Participant withdrawal
Participants can be withdrawn/excluded after randomi-
sation if:
 ► Surgery is cancelled after administration of 
anaesthesia. The patient can be reincluded later if 
possible.
 ► Surgery is rescheduled or changed after 
randomisation and eligibility is no longer upheld 
according to the inclusion and exclusion criteria.
 ► Postoperative complications make the patient 
unable to comply with study protocol for obtaining 
primary data (pain scores and PCA morphine data 
for 27 hours).
 ► Withdrawal of consent, before all primary data are 
obtained (pain scores and PCA morphine data for 
27 hours).
Participants meeting any of these criteria can be 
excluded from the trial after randomisation. No data 
will be analysed and they will be replaced by additional 
inclusion until the calculated sample size is included for 
ITT analysis. For safety reasons AEs will be registered for 
any excluded patients who have received the intervention 
(anaesthesia). An overview is shown in the flow diagram 
(figure 1).
Withdrawal of consent or failure to comply with the 
protocol after 27 hours postoperatively will not lead to 
exclusion from analysis of already collected data.
statistical plan
Primary outcome analysis
Pain scores and morphine data cannot be expected to 
follow normal distribution, and we expect to handle the 
primary outcome using non-parametric statistics. The IPS 
has been validated statistically with this in mind.23 It is 
derived from pain scores (NRS-AUC in our trial) and total 
morphine consumption. Both measures are ranked across 
both trial groups, and the IPS is calculated as deviation from 
mean rank in pain score added to deviation from mean 
rank in morphine, giving a result for each trial participant 
between −200% and +200%. The groups can be compared 
for significant difference with a distribution-independent 
permutation test and/or Mann-Whitney test, and effect size 
can be expressed by the ratio of mean rank or WMW odds.23
Analysis of the primary outcome will be performed 
as ‘intention-to-treat’ analysis including all consenting 
randomised patients not meeting the defined with-
drawal criteria. Additional ‘per-protocol’ analyses will be 
performed and include only participants who follow the 
protocol without the defined protocol violations.
Two-sided p values <0.05 will be considered statistically 
significant.
Secondary outcome analyses
Again, we expect to handle most outcomes using non-para-
metric statistics. However, some results such as NRS-AUC 
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measures may prove to resemble a normal distribution 
which, taken together with the fairly large sample size, 
warrants the use of parametric tests in order to obtain CIs 
on these estimates. In parametric models, we may include 
adjustment for expected heavy confounders, that is, age, 
diabetes and fracture severity (unimalleolar, bimalleolar 
or trimalleolar), as this can increase the accuracy of the 
estimate, even though the groups are expected to be 
comparable due to randomisation.
Subgroup analyses
Pain experience is known to vary with age and possibly 
gender.30 We have stratified randomisation in two 
age groups (≤60 or >60 years of age) and will perform 
subgroup analysis on relevant outcomes according to age 
group and gender.
Accountability procedure for missing data for analysis
Data for the primary outcome are registered from 0 to 
27 hours from time of anaesthesia. Missing data after this 
time (until the end of participation on postoperative day 
7) will not be replaced.
Some missing data are expected in the patient-reported 
NRS pain scores from 0 to 27 hours. Pragmatically we will 
fill in a missing measure point with the average of the 
two adjacent points, in effect drawing a line between 
them (linear interpolation), and thus allowing for AUC 
to be calculated. If the missing point is the last one (at 
27 hours), the value of the last observation is carried 
forward. If more than two 0–27 hours NRS scores are 
missing, the patient will be excluded from per-protocol 
analyses.
The measuring of rebound pain is performed over a 
period of 6 hours following patient-evaluated cessation of 
the sensory block. Should this period extend beyond the 
27-hour period, we will carry forward the last observation 
to extrapolate data. As the mean effect duration of the 
PNBs in our observational study was around 16 hours, we 
do not expect that extrapolation will be necessary. When 
Figure 1 AnAnkle Trial flow diagram. PNB, peripheral nerve block; SA, spinal anaesthesia.
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appropriate, we will perform sensitivity analyses to eval-
uate the impact of data extrapolation.
ethIcs and dIsseMInatIon
ethical and legislative approvals
AnAnkle Trial is conducted in accordance with applicable 
regulatory requirements and the study protocol, which 
is approved by the Regional Ethics Committees in the 
Capital Region of Denmark, the Danish Data Protection 
Agency and the Danish Health and Medical Authority. 
We follow national and international standards for good 
clinical practice (ICH GCP guidelines) and the recom-
mendations of the Consolidated Standards of Reporting 
Trials (CONSORT) Statement and extension in reporting 
randomised clinical pragmatic trials.31 The protocol was 
drafted following the Standard Protocol Items: Recom-
mendations for Interventional Trials (SPIRIT) guidelines 
accordingly (see online supplementary data 1).32 The 
project is monitored by the Copenhagen GCP unit.
Publication plan
We strive to readily publish the results in international 
peer-reviewed journals, and all the results will be made 
public, regardless of whether they come out positive, 
negative or inconclusive. Due to the complexity of the 
pain profiles, we intend to publish the results in at least 
two independent articles, with focus on the primary 
outcome measure and the secondary measure of rebound 
pain, respectively.
All authors must fulfil the criteria of the Vancouver 
convention.
dIscussIon
Regional anaesthesia is often preferred in ankle fracture 
surgery due to the superior safety profile and probably 
better postoperative pain control compared with general 
anaesthesia.17 19 33 To the best of our knowledge, AnAnkle 
Trial is the first study to thoroughly investigate the post-
operative pain profile and test which one of the most 
frequently used regional anaesthesia techniques is supe-
rior. Postoperative pain studies are often limited by large 
time intervals between pain registrations. We designed 
our trial to avoid this issue since it renders evaluation 
of the clinical significance of rebound pain impossible, 
because the rebound could be very intense yet completely 
undetected in-between pain scorings.
AnAnkle Trial constitutes a scientifically strong set-up, 
although blinding of the participants and investigators 
is not practically possible, which holds a potential risk of 
bias; for example, reported pain scores might be affected 
by psychological factors influenced by information from 
the investigators. To minimise this influence, all pain 
scores used for the primary outcome are registered by the 
participants, without consulting the staff. Likewise, the 
morphine data are gathered electronically from the PCA 
pump, which the patient activates without consulting the 
staff, thus ensuring a minimal risk of related bias. Finally, 
data analysis will be blinded. As in most other clinical 
trials, there remains a risk of sampling bias due to the 
eligibility criteria, which might impair the overall gener-
alisability of our results.
Among the strengths of the design are randomi-
sation and attention to sequence generation and 
allocation concealment to prevent selection bias between 
the two groups. The block randomisation and stratifi-
cation protect against bias from variability of practice 
during a relatively long inclusion period on different 
centres. We have chosen a composite score of pain assess-
ment and opioid consumption as primary outcome. The 
IPS has been thoroughly tested and proven to hold more 
statistical power than conventional comparisons of pain 
scores or morphine alone.23 There is a natural correlation 
between the two that can lead to failure in identifying a 
true effect, or even lead to finding a false-positive effect, 
on either outcome, when not balanced by evaluation of 
the other. In this study we will use the IPS with a longitu-
dinal pain measurement in the form of AUC pain score 
rather than a single pain rating. This allows us to illustrate 
the pain profile over time without letting the results be 
compromised by statistical mass significance. The indi-
vidual components of the IPS are separately analysed 
among various secondary endpoints to provide supple-
mentary details to the composite primary endpoint, as 
is recommended in the Initiative on Methods, Measure-
ment, and Pain Assessment in Clinical Trials (IMMPACT) 
consensus on pain trials.34
If AnAnkle Trial yields clear results, the implications on 
clinical practice could be profound. Fracture surgery is 
very common and optimising the choice of anaesthesia 
will have a major influence on the postoperative recovery 
and the overall patient course for a very large group of 
patients.
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